LTB4 Sweden

LTB4 Sweden Overview

Founded 2004
Status Out of Business
Employees 1
Latest Deal Type Liquidation

LTB4 Sweden General Information


Developer of small molecule intended to target diseases such as infections and cancer. The company's small molecule is made by using arachidonic acid metabolite leukotriene B4 (LTB4) to innate immunity system for targeting diseases, enabling patients to avail enhanced care without any side effects.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Primary Office
  • Kornhamstorg 53
  • 111 27 Stockholm
  • Sweden
+46 08-442 00 00
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

LTB4 Sweden Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Bankruptcy: Liquidation Completed Bankruptcy: Liquidation
1. Early Stage VC Completed Generating Revenue

LTB4 Sweden Executive Team (1)

Name Title Board Seat Contact Info
Carl-Johan Dalsgaard Ph.D Managing Director

Ready to get started?

Request a free trial